The Inducement Grant was granted pursuant to Aligos' 2024 Inducement Plan (the "Plan”) as an inducement material to this individual entering employment in accordance with Nasdaq Listing Rule 5635 (c) ...
H.C. Wainwright lowered the firm’s price target on Aligos Therapeutics (ALGS) to $70 from $75 and keeps a Buy rating on the shares. The firm is ...
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) had its price objective cut by equities research analysts at HC Wainwright from $75.00 to $70.00 in a research note issued on Tuesday,Benzinga ...
Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of -78.53% and 51.62%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock ...
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) is expected to be releasing its earnings data before the market opens on ...
Reports Q4 revenue $629k, consensus $433.33k. “2024 was a pivotal year for the company, paving the way for the future of Aligos,” stated ...
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best ...
Rostermania rages on in North America with many of Apex's biggest names finding themselves new homes. With year five of the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback